Discussion on "Article Review: Cancer control outcomes of Radium 223 pretreated lutetium 177 PSMA Radioligand vs Radium 223 na ve mCRPC patients"

Aldo Yang · 2025-04-07T16:47:28.942Z

Objectives This study investigated the cancer-control outcomes of Lutetium-177 prostate-specific membrane antigen radioligand therapy (Lu-177-PSMA) in metastatic castration-resistant prostate cancer (mCRPC) patients who were either pretreated with Ra...

Discussion on "Article Review: Cancer control outcomes of Radium 223 pretreated lutetium 177 PSMA Radioligand vs Radium 223 na ve mCRPC patients" | Hashnode

Search Hashnode

Article Review: Cancer control outcomes of Radium 223 pretreated lutetium 177 PSMA Radioligand vs Radium 223 na ve mCRPC patients

Responses